Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

90

datasets available to search

ShareScore release 0.7.1

Reset

Dataset results

90 results for “schistosomiasis”

Learn how ShareScore rates datasets ↗
dryad36/100

Knowledge, experiences, and practices of women affected by female genital schistosomiasis in rural Madagascar

Open the record for dataset details and reuse information.

publicJul 2022View details →
dryad36/100

Oxamniquine derivatives overcome praziquantel treatment limitations for schistosomiasis

Open the record for dataset details and reuse information.

publicJun 2023View details →
zenodo32/100

Schistosomiasis and soil-transmitted helminthiasis preventive chemotherapy: Adverse events in children from 2 to 15 years in Bengo province, Angola - Dataset

<p>In the context of a targeted drug administration, between December 2012 and September 2013, we conducted two surveys after co-administrating single oral doses of praziquantel and albendazole tablets to children 2 to 15 years of age. About 24 hours after each treatment, participants answered a questionnaire about adverse events. At baseline, 605 children (55.0% male; mean age: 9.7 years) were treated; 460 were interviewed and 257 (55.9%) reported at least one adverse event, 62.3% (160/257) of children being infected with<em> schistosoma haematobium</em>. After six months of treatment, among 339 children surveyed, 184 (54.3%) reported adverse events, with 49.5% (91/184) of infected children. Adverse events were most common in preschool-aged children, with no significant difference between genders. The most frequent adverse events in the two surveys were abdominal pain (18.5%, 25.7%), headache (20.9%, 23.0%) and dizziness (15.7%, 19.8%). Children aged 12 to 15 years (adjusted OR=0.40, <em>p</em>=0.040) and those with mixed infection (adjusted OR=0.04<em>, p</em>=0.011) had lower odds of adverse events. After the second treatment, those with heavy infection (adjusted OR=2.72<em>, p</em>=0.018) and aged 9-11 years (adjusted OR=2.01, <em>p</em>=0.049) had significantly fewer adverse events. About 2.0% of children experienced severe adverse events.</p>

opencc-by-4.0Feb 2020View details →
dryad32/100

Data from: Epidemiological interactions between urogenital and intestinal human schistosomiasis in the context of praziquantel treatment across three West African countries

Background: In many parts of sub-Saharan Africa, urogenital and intestinal schistosomiasis co-occur, and mixed species infections containing both Schistosoma haematobium and S. mansoni can be common. During co-infection, interactions between these two species are possible, yet the extent to which such interactions influence disease dynamics or the outcome of control efforts remains poorly understood. Methodology/Principal Findings: Here we analyse epidemiological data from three West African countries co-endemic for urogenital and intestinal schistosomiasis (Senegal, Niger and Mali) to test whether the impact of praziquantel (PZQ) treatment, subsequent levels of re-infection or long-term infection dynamics are altered by co-infection. In all countries, positive associations between the two species prevailed at baseline: infection by one species tended to predict infection intensity for the other, with the strength of association varying across sites. Encouragingly, we found little evidence that co-infection influenced PZQ efficacy: species-specific egg reduction rates (ERR) and cure rates (CR) did not differ significantly with co-infection, and variation in treatment success was largely geographical. In Senegal, despite positive associations at baseline, children with S. mansoni co-infection at the time of treatment were less intensely re-infected by S. haematobium than those with single infections, suggesting competition between the species may occur post-treatment. Furthermore, the proportion of schistosome infections attributable to S. mansoni increased over time in all three countries examined. Conclusions/Significance: These findings suggest that while co-infection between urinary and intestinal schistosomes may not directly affect PZQ treatment efficacy, competitive interspecific interactions may influence epidemiological patterns of re-infection post-treatment. While re-infection patterns differed most strongly according to geographic location, interspecific interactions also seem to play a role, and could cause the community composition in mixed species settings to shift as disease control efforts intensify, a situation with implications for future disease management in this multi-species system.

opencc-zeroDec 2014View details →
ClinicalTrials.gov32/100

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)

ClinicalTrials.gov study NCT02868385. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis

ClinicalTrials.gov study NCT01869465. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding

ClinicalTrials.gov study NCT02755324. IPD Sharing: UNDECIDED. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis

ClinicalTrials.gov study NCT01512277. IPD Sharing: Not stated. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children

ClinicalTrials.gov study NCT03799510. IPD Sharing: NO. Countries: 1. Publications: 6.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Effect of Artemisinin-based Combination Therapies on Schistosomiasis on Malaria Co-infection

ClinicalTrials.gov study NCT04264130. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa

ClinicalTrials.gov study NCT01154907. IPD Sharing: YES. Countries: 1. Publications: 16.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Arachidonic Acid Treatment Against Schistosomiasis Infection in Children

ClinicalTrials.gov study NCT02144389. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal

ClinicalTrials.gov study NCT01553552. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Schistosomiasis in Senegal

ClinicalTrials.gov study NCT03187366. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Health Benefits of Repeated Treatment in Pediatric Schistosomiasis

ClinicalTrials.gov study NCT01424410. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children

ClinicalTrials.gov study NCT03893097. IPD Sharing: YES. Countries: 1. Publications: 2.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study

ClinicalTrials.gov study NCT04115072. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults

ClinicalTrials.gov study NCT03110757. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia

ClinicalTrials.gov study NCT00276224. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact

ClinicalTrials.gov study NCT02194712. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record